Early response of bone metastases can predict tumor response in patients with non‑small‑cell lung cancer with bone metastases in the treatment with nivolumab

Nakata,Eiji; Sugihara,Shinsuke; Sugawara,Yoshifumi; Kozuki,Toshiyuki; Harada,Daijiro; Nogami,Naoyuki; Nakahara,Ryuichi; Furumatsu,Takayuki; Tetsunaga,Tomonori; Kunisada,Toshiyuki; Ozaki,Toshifumi

doi:10.3892/ol.2020.11856

Early response of bone metastases can predict tumor response in patients with non‑small‑cell lung cancer with bone metastases in the treatment with nivolumab

Authors:
- Eiji Nakata
- Shinsuke Sugihara
- Yoshifumi Sugawara
- Toshiyuki Kozuki
- Daijiro Harada
- Naoyuki Nogami
- Ryuichi Nakahara
- Takayuki Furumatsu
- Tomonori Tetsunaga
- Toshiyuki Kunisada
- Toshifumi Ozaki
View Affiliations

Affiliations: Department of Orthopedic Surgery, Okayama University Hospital, Okayama 700‑8558, Japan, Department of Orthopedic Surgery, Shikoku Cancer Center, Matsuyama, Ehime 791‑0280, Japan, Department of Radiology, Shikoku Cancer Center, Matsuyama, Ehime 791‑0280, Japan, Department of Thoracic Oncology and Medicine, Shikoku Cancer Center, Matsuyama, Ehime 791‑0280, Japan
Published online on: July 10, 2020 https://doi.org/10.3892/ol.2020.11856
Pages: 2977-2986

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The effect of nivolumab and the relation between bone response and tumor control in patients with non‑small‑cell lung cancer (NSCLC) with bone metastases are not clear. The outcome of nivolumab monotherapy was investigated, and whether the response of bone metastases is useful as an early predictor of tumor control in patients with NSCLC with bone metastases was examined. The participants included 15 patients who received nivolumab monotherapy for NSCLC with bone metastases in our institution between 2015 and 2017. Tumor control was defined using Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST1.1). Response of bone metastases was assessed by the MD Anderson response criteria (MDA criteria). Responses according to RECIST1.1 and the MDA criteria were classified as responder (complete response or partial response) and non‑responder [progressive disease (PD) or stable disease]. Progression‑free survival (PFS) was investigated using the Kaplan‑Meier method. With RECIST1.1, the overall response rate was 20%. Multivariate analysis showed that the MDA criteria were the only risk factor for patients with PD (RECIST1.1). Median PFS was 1.9 months, with PFS of 20% at 6 months. Univariate analysis showed that being a non‑responder according to the MDA criteria was the only risk factor for PFS. In patients who were responders (MDA criteria) within 3 months, PFS was 83 and 50% at 3 and 6 months, respectively, though all non‑responder (MDA criteria) patients converted to PD (RECIST1.1) within 3 months. Response according to RECIST1.1 was significantly correlated with response according to the MDA criteria (P<0.05). In patients who were both responders according to RECIST1.1 and the MDA criteria, time to response with the MDA criteria (1.4‑2.0 months) was earlier than with RECIST1.1 (2.8‑3.0 months) in all patients. In conclusion, application of the MDA criteria within 2 months of nivolumab monotherapy is useful for early prediction of response and prognosis in patients with NSCLC with bone metastases.

View Figures

View References

1	Darvin P, Toor SM, Sasidharan Nair V and Elkord E: Immune checkpoint inhibitors: Recent progress and potential biomarkers. Exp Mol Med. 50:1–11. 2018. View Article : Google Scholar : PubMed/NCBI
2	Postow MA, Callahan MK and Wolchok JD: Immune checkpoint blockade in cancer therapy. J Clin Oncol. 33:1974–1982. 2015. View Article : Google Scholar : PubMed/NCBI
3	LaFleur MW, Muroyama Y, Drake CG and Sharpe AH: Inhibitors of the PD-1 pathway in tumor therapy. J Immunol. 200:375–383. 2018. View Article : Google Scholar : PubMed/NCBI
4	Zhang T, Xie J, Arai S, Wang L, Shi X, Shi N, Ma F, Chen S, Huang L, Yang L, et al: The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: A meta-analysis. Oncotarget. 7:73068–73079. 2016. View Article : Google Scholar : PubMed/NCBI
5	Hida T, Nishio M, Nogami N, Ohe Y, Nokihara H, Sakai H, Satouchi M, Nakagawa K, Takenoyama M, Isobe H, et al: Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer. Cancer Sci. 108:1000–1006. 2017. View Article : Google Scholar : PubMed/NCBI
6	Nishio M, Hida T, Atagi S, Sakai H, Nakagawa K, Takahashi T, Nogami N, Saka H, Takenoyama M, Maemondo M, et al: Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer. ESMO Open. 1:e0001082017. View Article : Google Scholar : PubMed/NCBI
7	Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, et al: Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial. Lancet Oncol. 16:257–265. 2015. View Article : Google Scholar : PubMed/NCBI
8	Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
9	Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
10	Brodowicz T, O'Byrne K and Manegold C: Bone matters in lung cancer. Ann Oncol. 23:2215–2222. 2012. View Article : Google Scholar : PubMed/NCBI
11	Tsuya A, Kurata T, Tamura K and Fukuoka M: Skeletal metastases in non-small cell lung cancer: A retrospective study. Lung Cancer. 57:229–232. 2007. View Article : Google Scholar : PubMed/NCBI
12	Hamaoka T, Costelloe CM, Madewell JE, Liu P, Berry DA, Islam R, Theriault RL, Hortobagyi GN and Ueno NT: Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. Br J Cancer. 102:651–657. 2010. View Article : Google Scholar : PubMed/NCBI
13	Costelloe CM, Chuang HH, Madewell JE and Ueno NT: Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST. J Cancer. 1:80–92. 2010. View Article : Google Scholar : PubMed/NCBI
14	Hayashi N, Costelloe CM, Hamaoka T, Wei C, Niikura N, Theriault RL, Hortobagyi GN, Madewell JE and Ueno NT: A prospective study of bone tumor response assessment in metastatic breast cancer. Clin Breast Cancer. 13:24–30. 2013. View Article : Google Scholar : PubMed/NCBI
15	Yamashita Y, Aoki T, Hanagiri T, Yoshii C, Mukae H, Uramoto H and Korogi Y: Osteosclerotic lesions in patients treated with gefitinib for lung adenocarcinomas: A sign of favorable therapeutic response. Skeletal Radiol. 41:409–414. 2012. View Article : Google Scholar : PubMed/NCBI
16	Rong D, Mao Y, Yang Q, Xu S, Zhao Q and Zhang R: Early osteosclerotic changes predict chemotherapy response in non-small-cell lung cancer patients with bone metastases. Eur Radiol. 28:4362–4369. 2018. View Article : Google Scholar : PubMed/NCBI
17	Chang CY, Simeone FJ, Torriani M and Bredella MA: Quantitative contrast-enhanced CT attenuation evaluation of osseous metastases following chemotherapy. Skeletal Radiol. 46:1385–1395. 2017. View Article : Google Scholar : PubMed/NCBI
18	Amir E, Whyne C, Freedman OC, Fralick M, Kumar R, Hardisty M and Clemons M: Radiological changes following second-line zoledronic acid treatment in breast cancer patients with bone metastases. Clin Exp Metastasis. 26:479–484. 2009. View Article : Google Scholar : PubMed/NCBI
19	Vassiliou V, Kalogeropoulou C, Christopoulos C, Solomou E, Leotsinides M and Kardamakis D: Combination ibandronate and radiotherapy for the treatment of bone metastases: Clinical evaluation and radiologic assessment. Int J Radiat Oncol Biol Phys. 67:264–272. 2007. View Article : Google Scholar : PubMed/NCBI
20	Quattrocchi CC, Piciucchi S, Sammarra M, Santini D, Vincenzi B, Tonini G, Grasso RF and Zobel BB: Bone metastases in breast cancer: Higher prevalence of osteosclerotic lesions. Radiol Med. 112:1049–1059. 2007.(In Italian). View Article : Google Scholar : PubMed/NCBI
21	Nakata E, Sugihara S, Kataoka M, Yamashita N, Furumatsu T, Takigawa T, Tetsunaga T and Ozaki T: Early response assessment of re-ossification after palliative conventional radiotherapy for vertebral bone metastases. J Orthop Sci. 24:332–336. 2019. View Article : Google Scholar : PubMed/NCBI
22	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
23	Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, Powderly J, Heist R, Sequist LV, Smith DC, et al: Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: Results from the CA209-003 study. J Clin Oncol. 36:1675–1684. 2018. View Article : Google Scholar : PubMed/NCBI
24	Nadal E, Massuti B, Dómine M, García-Campelo R, Cobo M and Felip E: Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: Insights from long-term survivors. Cancer Immunol Immunother. 68:341–352. 2019. View Article : Google Scholar : PubMed/NCBI
25	Blons H, Garinet S, Laurent-Puig P and Oudart JB: Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update. J Thorac Dis. 11 (Suppl 1):S25–S36. 2019. View Article : Google Scholar : PubMed/NCBI
26	Prelaj A, Tay R, Ferrara R, Chaput N, Besse B and Califano R: Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer. Eur J Cancer. 106:144–159. 2019. View Article : Google Scholar : PubMed/NCBI
27	Yoneda T and Hiraga T: Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun. 328:679–687. 2005. View Article : Google Scholar : PubMed/NCBI
28	Sterling JA, Edwards JR, Martin TJ and Mundy GR: Advances in the biology of bone metastasis: How the skeleton affects tumor behavior. Bone. 48:6–15. 2011. View Article : Google Scholar : PubMed/NCBI